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Polyarteritis nodosa and parvovirus B19
infection
SIR,-Parvovirus B19 is the agent most commonly responsible
for acute arthritis in children and adults and several reports have
described parvovirus infection presenting with vascular purpura. 3-5
Although infection with human parvovirus B19 has not been
previously associated with polyarteritis nodosa, parvovirus
infection has been associated with arteritis in animals, specifically in
Aleutian minks,6 in whom a chronic wasting disease develops,
eventually resulting in death. The clinical spectrum of human
parvovirus B19 is still expanding; brachial plexus neuropathy
associated with acute infection has been reported.’’ We present a
patient with biopsy-proven polyarteritis nodosa that developed
concurrently with serological evidence of acute infection with
parvovirus B 19.
A 57-year-old white woman noted a sore red lump on the lateral
right calf in January, 1991, which reached a diameter of 10 cm eight
weeks later. Biopsy of the lesion was done, and she also underwent a
total abdominal hysterectomy for post-menopausal bleeding.
Biopsy showed necrotising vasculitis of polyarteritis nodosa type
(PAN). Other symptoms included severe headaches, nausea,
vomiting, migratory arthralgias of the hands, and intermittent
’foul-smelling diarrhoea without abdominal pain, and she had lost
4 kg in weight. She had had hepatitis as a child, oligoarthritis of the
right knee and ankle in 1982 that resolved with anti-inflammatory
drugs over a few months, trigeminal neuralgia in the remote past,
and left bundle branch block for several years. She did not smoke or
drink. She had been started on premarin 0-625 mg and fluoxetine
20 mg daily after hysterectomy. In April, 1991, her blood pressure
was 180/100 mm Hg. She had a painful papular erythematous rash
of the hard palate. A residual tender nodule of the right calf 3 cm in
diameter was still palpable under the biopsy scar. Cardiopulmonary
examination revealed a loud first heart sound without a murmur and
clear lungs. Liver span was 10 cm, the spleen tip was palpable, and
she had numbness of the right foot in the distribution of the
superficial peroneal nerve.
Complete and differential blood counts and chemistry profile
were normal. Westergren sedimentation rate was 86 mm/h and
urine analysis showed trace protein and 20-50 red cells with
occasional white cells. Rheumatoid factor was negative, antinuclear
antibody 1/40 homogeneous. Creatine kinase and C3 and C4
complement concentrations were normal. Antineutrophil
cytoplasmic antibody was negative, as were antibodies to hepatitis B
and C viruses from Borrelia burgdorferi. IgM antibodies to human
parvovirus B19 were positive by western blot, whereas IgG
antibodies were absent. A month later IgM antibodies were
undetectable and IgG antibodies to this virus developed, which was
consistent with serological conversion due to acute infection.
ELISA tests were not available at our institution at the time. A
D-xylose breath test was abnormal, suggesting malabsorption or
injury of the bowel wall. She was started on antihypertensive drugs,
oral cyclophosphamide 2 mg/kg daily, and prednisone 1 mg/kg
daily, and has done well. Re-examination of organs removed at
hysterectomy failed to show evidence of PAN.
PAN is a necrotising vasculitis that affects the small and
medium-sized muscular arteries and has been described in
association with viral infections, especially hepatitis B virus.8
Hepatitis C virus has been reported as a cause of small-vessel
vasculitiS.8,9 Purpuric vasculitis of the smaller veins, arterioles, and
capillaries can be the presenting feature of human parvovirus B19
&Igrave;nfection.3,5 As far as we are aware PAN in association with acute
parvovirus B19 infection has not been reported in man. Our patient
had polyarteritis nodosa proven by biopsy of a subcutaneous leg
nodule and had evidence suggestive of acute infection with human
parvovirus B19. Parvovirus antibody investigation was sought on
the assumption that a positive IgG antibody response to parvovirus
B19 might explain the episode of self-limited oligoarthritis that she
had in 1982. Whether the evidence for acute infection with
parvovirus B19 was coincidental to the development of the arteritis
or a re-exacerbation of an earlier infection, it is likely that infection
with this virus triggered the PAN syndrome, especially since
arteritis is known to be associated with parvovirus infection in other
species.5 The serological findings compatible with acute infection
were unexpected. We believe that her episode of oligoarthritis in
1982 was due to parvovirus B19 and the later episode of PAN was
secondary to a relapse or re-exacerbation of the parvovirus infection.
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Is fever really a "side-effect" of biological
response modifiers?
SIR,-In clinical trials of biological response modifiers such as
tumour necrosis factor and interleukin-2 in cancer, fever tends to be
identified as a "side-effect", so it is treated with paracetamol
(acetaminophen) or some other analgesic/antipyretic drug. In the
late 1800s some forms of cancer were treated by injections of
"Coley’s toxins", living cultures of Streptococcus pyogenes often
mixed with other species of bacteria. It is probable that the fevers
that developed in these patients were not reduced with antipyretic
drugs. Indeed in the past two decades it has become clear that fever
is a phylogenetically ancient event1 and that increases in body
temperature of the magnitude seen during fever have profound
effects on specific and non-specific immunity.’-3 It seems that fever
enhances host defences. Since many tumours seem more sensitive
to increases in temperature than normal cells are, I suggest that
before fever in patients on treatment with biological response
modifiers is "treated", careful consideration be given to the
possibility that the fever might be helping the patient to rid himself
or herself of the tumour.
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Lack of effect of somatostatin and
analogues in lymphorrhagia from ruptured
thoracic duct
SiR,&mdash;The management of a chylothorax from a ruptured
thoracic duct remains controversial Ulibarri et al2 have claimed
that intravenous administration of somatostatin may strongly
reduce lymphorrhagia. By analogy with the effect of somatostatin
on intestinal fistulae, such a beneficial effect would be of interest in
the treatment of a high output of lymphorrhagia.3 We report two
cases of lymphorrhagia in which somatostatin or longacting
somatostatin analogue (’Sandostatin’) were used.
Patient 1-A 40-year-old man presented with a large apical mass
in the left lung. The resected tumour weighed 1500 g and was
histologically defmed as a benign schwannoma. On the third
